CRISPR Therapeutics (CRSP) Stock Analysis Report

General Information

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics.

Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

CRISPR Therapeutics (CRSP) Stock Graph

How We Grade CRISPR Therapeutics (CRSP)

We grade stocks based on past performance, their future growth potential, intrinsic value, dividend history, and overall financial health.

The chart below shows how we grade CRISPR Therapeutics (CRSP) across the board compared to its closest peers.

Benzinga Edge Rankings

Benzinga Edge stock rankings give you four critical scores to help you identify the strongest and weakest stocks to buy and sell.

81.53

Momentum measures a stock's relative strength based on its price movement patterns and volatility over multiple timeframes, ranked as a percentile against other stocks.

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Peer Ratings

See how CRISPR Therapeutics compares to its peers in these key performance metrics from Benzinga Rankings.

Top Peers

Value

Quality

Growth

Momentum

Short

Medium

Long

ACLXArcellx

80.7

COGTCogent Biosciences

99.41

PTGXProtagonist Therapeutics

4.19

94.35

LEGNLegend Biotech

26.05

Short: price trend over the last couple of months

Medium: price trend over the last couple of quarters

Long: price trend over the past year

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Future Growth

Our estimate of future price growth is based on an aggregation of 7 analyst ratings over the past 3 months and their 12-month price targets.

Below, you can see that analysts are estimating a 12-month price target range of $44.00 - $93.00 with an average of $71.88

31.64%

Expected movement for CRISPR Therapeutics (CRSP) over the next 12 months

Based on these rankings

Recent Ratings for CRISPR Therapeutics (CRSP)

Citigroup

Date:

Nov 12, 2025

Action:

Maintains

Prev. Target:

$87.00

New Target:

$77.00

RBC Capital

Date:

Nov 11, 2025

Action:

Maintains

Prev. Target:

$42.00

New Target:

$50.00

Baird

Date:

Nov 11, 2025

Action:

Maintains

Prev. Target:

$52.00

New Target:

$44.00

Needham

Date:

Nov 10, 2025

Action:

Maintains

Prev. Target:

$81.00

New Target:

$80.00

B of A Securities

Date:

Oct 17, 2025

Action:

Maintains

Prev. Target:

$78.00

New Target:

$93.00

Needham

Date:

Oct 10, 2025

Action:

Reiterates

Prev. Target:

$81.00

New Target:

$81.00

HC Wainwright & Co.

Date:

Sep 23, 2025

Action:

Reiterates

Prev. Target:

$80.00

New Target:

$80.00

Past Performance

How has CRISPR Therapeutics (CRSP) performed over the past 5 years?

The two main factors that we consider when analyzing past performance is overall return and volatility

Using these two metrics, we can determine if this stock gave its investors enough return for the risk that they took on by owning it. This is measured by the sharpe ratio, which has been used as a primary measure of risk/reward trade-off for almost 60 years.

This ratio can be interpreted as the amount of return an investor has received for the amount of risk that they took on by owning the stock over that timeframe.

CRISPR Therapeutics (CRSP) sharpe ratio over the past 5 years is -0.6767 which is considered to be below average compared to the peer average of 0.8497

Analyzing CRISPR Therapeutics (CRSP) Recent Options Activity

Below, you can see the trend in options sentiment over the past 30 days.

Based on our data, CRSP's options trades have recently carried more negative sentiment than positive.

Company Financials

INCOME STATEMENT

The income statement also known as the profit and loss statement, primarily focuses on the company's revenues and expenses during a particular period.

The main purpose of an income statement is to convey details of profitability and business activities. Below, is CRSP's income statement for the previous four years along with its trailing-twelve- month profit & loss.

FISCAL YEAR (BIL.)

2021 ($)

2022 ($)

2023 ($)

2024 ($)

TTM ($)

Total Revenue

0.91

0.00

0.37

0.04

Operating Revenue

0.91

0.00

0.37

0.04

Cost Of Revenue

0.00

0.11

0.13

0.11

0.16

Gross Profit

0.00

-0.11

0.24

-0.08

-0.12

Operating Expense

0.54

0.56

0.46

0.39

0.45

Selling General And Administration

0.10

0.08

0.07

Research and Development

0.44

0.46

0.39

0.32

0.38

Operating Income

0.37

-0.67

-0.22

-0.47

-0.57

Net Non-Operating Interest Income Expense

0.00

Other Income Expense

0.01

0.02

0.07

0.10

0.09

Other Non-Operating Income Expenses

0.01

0.02

0.07

0.10

0.09

Pre-Tax Income

0.38

-0.65

-0.15

-0.36

-0.48

Tax Provision

0.00

Net Income

0.38

-0.65

-0.15

-0.37

-0.49

Net Income Common Stockholders

0.38

-0.65

-0.15

-0.37

-0.49

Total Operating Income As Reported

0.37

-0.67

-0.22

-0.47

-0.57

Total Expenses

0.54

0.67

0.59

0.50

0.61

Net Income From Continuing And Discontinued Operation

0.38

-0.65

-0.15

-0.37

-0.49

Normalized Income

0.38

-0.65

-0.15

-0.37

-0.49

Interest Income

0.00

Interest Expense

0.00

Net Interest Income

0.00

EBIT

0.37

-0.67

-0.22

-0.47

-0.57

EBITDA

0.39

-0.65

-0.20

-0.45

-0.56

Reconciled Cost Of Revenue

0.00

0.11

0.13

0.11

0.16

Reconciled Depreciation

0.02

Normalized EBITDA

0.39

-0.65

-0.20

-0.45

-0.56

Tax Rate For Calcs

0.00

0.09

Tax Effect Of Unusual Items

0.00

BALANCE SHEET

The balance sheet is a snapshot of a companies financials during a particular period in time.

It breaks down what company owns (assets) and what a company owes (liabilities), in order to give investors an overview of its capital structure.

FISCAL YEAR (BIL.)

2021 ($)

2022 ($)

2023 ($)

2024 ($)

TTM ($)

Total Assets

2.75

2.24

2.23

2.24

2.25

Current Assets

2.42

1.85

1.91

1.94

1.93

Total Non-Current Assets

0.33

0.39

0.32

0.30

0.32

Total Liabilities Net Minority Interest

0.35

0.37

0.35

0.31

0.33

Current Liabilities

0.12

0.11

0.09

0.12

Other Non-Current Liabilities

0.01

0.00

0.01

Total Equity Gross Minority Interest

2.40

1.88

1.93

1.92

Stockholders Equity

0.00

Total Capitalization

2.40

1.88

1.93

1.92

Common Stock Equity

2.40

1.88

1.93

1.92

Net Tangible Assets

2.40

1.88

1.93

1.92

Working Capital

2.30

1.73

1.80

1.85

1.81

Invested Capital

2.40

1.88

1.93

1.92

Tangible Book Value

2.40

1.88

1.93

1.92

Total Debt

0.23

0.24

0.22

0.21

Net Debt

0.00

Share Issued

0.08

0.09

Ordinary Shares Number

0.08

0.09

CASH FLOW STATEMENTS

A companies statement of cash flows gives an investor a break down of the cash inflows and outflows from a companies operations and investment activities.

FISCAL YEAR (BIL.)

2021 ($)

2022 ($)

2023 ($)

2024 ($)

TTM ($)

Cash Flow from Continuing Operating Activities

0.54

-0.50

-0.26

-0.14

-0.30

Net Income from Continuing Operations

0.38

-0.65

-0.15

-0.37

-0.49

Depreciation and Amortization

0.02

Deferred Tax

—

Deferred Income Tax

—

Stock-Based Compensation

0.10

0.08

0.09

0.08

Other Non-Cash Items

—

0.01

-0.01

-0.04

0.07

Change in Working Capital

0.03

0.02

-0.19

0.16

0.02

Change in Receivables

—

-0.20

0.18

—

Changes in Account Receivables

—

-0.20

0.18

—

Change in Inventory

—

Change in Payables and Accrued Expense

0.04

0.01

-0.02

-0.03

0.03

Change in Payable

—

Change in Account Payable

—

Change in Other Current Assets

—

Change in Other Current Liabilities

-0.01

—

0.01

—

Change in Other Working Capital

0.01

—

-0.01

Cash Flow from Continuing Investing Activities

-1.04

-0.26

0.37

-0.28

0.04

Net PPE Purchase and Sale

-0.08

-0.04

-0.01

—

Net Business Purchase and Sale

—

Purchase of Business

—

Net Investment Purchase and Sale

-0.95

-0.22

0.39

-0.28

0.06

Purchase of Investment

-1.51

-1.42

-1.07

-1.49

-1.02

Sale of Investment

0.56

1.20

1.45

1.21

1.08

Net Other Investing Changes

—

Financing Cash Flow

0.25

0.04

0.06

0.33

Cash Flow from Continuing Financing Activities

0.25

0.04

0.06

0.33

Net Issuance Payments of Debt

—

Net Long-Term Debt Issuance

—

Long-Term Debt Issuance

—

Long-Term Debt Payments

—

Net Short-Term Debt Issuance

—

Net Common Stock Issuance

0.21

—

0.30

Common Stock Issuance

0.21

—

0.30

Common Stock Payments

—

Cash Dividends Paid

—

Net Other Financing Charges

—

End Cash Position

4.78

1.95

1.75

1.76

1.06

Changes in Cash

-0.25

-0.72

0.18

-0.09

0.06

Beginning Cash Position

5.02

2.66

1.58

1.85

1.00

Capital Expenditure

-0.08

-0.04

-0.01

—

-0.03

Issuance of Capital Stock

0.21

—

0.30

Issuance of Debt

—

Repayment of Debt

—

Repurchase of Capital Stock

—

Free Cash Flow

0.46

-0.53

-0.27

-0.14

-0.33